IL161165A0 - Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist - Google Patents

Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Info

Publication number
IL161165A0
IL161165A0 IL16116502A IL16116502A IL161165A0 IL 161165 A0 IL161165 A0 IL 161165A0 IL 16116502 A IL16116502 A IL 16116502A IL 16116502 A IL16116502 A IL 16116502A IL 161165 A0 IL161165 A0 IL 161165A0
Authority
IL
Israel
Prior art keywords
telmisartan
same
sodium salt
crystalline sodium
angiotensin antagonist
Prior art date
Application number
IL16116502A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161165(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL161165A0 publication Critical patent/IL161165A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16116502A 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist IL161165A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (de) 2001-10-31 2001-10-31 Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
PCT/EP2002/011394 WO2003037876A1 (de) 2001-10-31 2002-10-11 Kristallines natriumsalz des telmisartans und dessen verwendung als angiotensin antagonist

Publications (1)

Publication Number Publication Date
IL161165A0 true IL161165A0 (en) 2004-08-31

Family

ID=7704331

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16116502A IL161165A0 (en) 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
IL161165A IL161165A (en) 2001-10-31 2004-03-30 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161165A IL161165A (en) 2001-10-31 2004-03-30 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Country Status (35)

Country Link
EP (1) EP1442023B1 (es)
JP (1) JP5124076B2 (es)
KR (1) KR100929502B1 (es)
CN (1) CN100509789C (es)
AR (1) AR037148A1 (es)
AT (1) ATE370125T1 (es)
AU (1) AU2002338886B2 (es)
BR (1) BR0213568A (es)
CA (1) CA2463146C (es)
CO (1) CO5580785A2 (es)
CY (1) CY1107504T1 (es)
DE (2) DE10153737A1 (es)
DK (1) DK1442023T3 (es)
EA (1) EA007596B1 (es)
EC (1) ECSP045089A (es)
ES (1) ES2291505T3 (es)
HK (1) HK1073841A1 (es)
HR (1) HRPK20040372B3 (es)
HU (1) HUP0402391A3 (es)
IL (2) IL161165A0 (es)
ME (1) MEP43608A (es)
MX (1) MXPA04004013A (es)
MY (1) MY129741A (es)
NO (1) NO326465B1 (es)
NZ (1) NZ532716A (es)
PE (1) PE20030629A1 (es)
PL (1) PL211462B1 (es)
PT (1) PT1442023E (es)
RS (1) RS50879B (es)
SA (1) SA02230419B1 (es)
SI (1) SI1442023T1 (es)
TW (2) TWI341200B (es)
UA (1) UA82833C2 (es)
UY (1) UY27520A1 (es)
WO (1) WO2003037876A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
KR100908308B1 (ko) * 2004-05-05 2009-07-17 테바 파마슈티컬 인더스트리즈 리미티드 순도가 높은 칸데사르탄 실렉세틸의 제조
EP1805146A4 (en) 2004-10-18 2009-01-14 Reddys Lab Ltd Dr PROCESS FOR THE PREPARATION OF TELMISARTAN
KR20070072588A (ko) * 2004-11-03 2007-07-04 테바 파마슈티컬 인더스트리즈 리미티드 텔미사르탄 나트륨의 비정질형 및 다형
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (de) * 2008-07-29 2010-02-10 Sandoz AG Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
DK2432452T3 (en) 2009-05-20 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutically telmisartan drink solution
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
WO2012055941A1 (en) 2010-10-27 2012-05-03 Krka,Tovarna Zdravil, D. D., Novo Mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
US9561610B2 (en) * 2011-06-24 2017-02-07 Honda Motor Co., Ltd. Injection molding method and apparatus therefor
PL3421470T3 (pl) 2011-11-25 2021-08-02 Adverio Pharma Gmbh Podstawione 5-fluoro-1H-pirazolopirydyny w postaci krystalicznej
DK3209647T3 (da) 2014-10-21 2020-08-24 Ariad Pharma Inc Krystallinske former af 5-chlor-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidin-2,4-diamin
KR101872726B1 (ko) * 2016-07-28 2018-06-29 주식회사 씨트리 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
KR20200026975A (ko) 2017-07-07 2020-03-11 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
JP2022517610A (ja) * 2019-01-10 2022-03-09 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー(シージアチュアン)カンパニー,リミテッド 複素環化合物塩およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
ATE230263T1 (de) * 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
DE19901921C2 (de) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Also Published As

Publication number Publication date
CN1578772A (zh) 2005-02-09
MXPA04004013A (es) 2004-06-18
SI1442023T1 (sl) 2007-12-31
HUP0402391A3 (en) 2010-03-29
HUP0402391A2 (hu) 2005-03-29
PT1442023E (pt) 2007-09-17
CA2463146A1 (en) 2003-05-08
NO326465B1 (no) 2008-12-08
HRPK20040372B3 (en) 2006-02-28
MY129741A (en) 2007-04-30
SA02230419B1 (ar) 2007-07-31
JP2005536445A (ja) 2005-12-02
JP5124076B2 (ja) 2013-01-23
CY1107504T1 (el) 2013-03-13
UA82833C2 (uk) 2008-05-26
EA200400479A1 (ru) 2004-10-28
HRP20040372A2 (en) 2004-10-31
TW200300082A (en) 2003-05-16
UY27520A1 (es) 2003-05-30
NZ532716A (en) 2007-06-29
ES2291505T3 (es) 2008-03-01
DK1442023T3 (da) 2007-11-05
PL367477A1 (en) 2005-02-21
DE10153737A1 (de) 2003-05-28
CO5580785A2 (es) 2005-11-30
KR100929502B1 (ko) 2009-12-03
KR20050035172A (ko) 2005-04-15
DE50210719D1 (de) 2007-09-27
EP1442023B1 (de) 2007-08-15
WO2003037876A1 (de) 2003-05-08
TWI333419B (en) 2010-11-21
PE20030629A1 (es) 2003-07-14
EP1442023A1 (de) 2004-08-04
AR037148A1 (es) 2004-10-27
PL211462B1 (pl) 2012-05-31
MEP43608A (en) 2011-02-10
RS50879B (sr) 2010-08-31
TWI341200B (en) 2011-05-01
IL161165A (en) 2009-12-24
HK1073841A1 (en) 2005-10-21
ECSP045089A (es) 2004-06-28
TW201034664A (en) 2010-10-01
EA007596B1 (ru) 2006-12-29
YU36304A (sh) 2006-08-17
BR0213568A (pt) 2004-09-08
ATE370125T1 (de) 2007-09-15
AU2002338886B2 (en) 2008-04-17
CA2463146C (en) 2011-01-25
NO20041758L (no) 2004-04-29
CN100509789C (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
IL161165A0 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
AU2002338886A1 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
HK1139681A1 (en) Salts of valsartan
EP1683784A4 (en) DIIMONIUM SALT CONNECTION AND ITS USE
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
EP1387680A4 (en) AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE
IL169336A0 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
HK1151511A1 (en) Preparation and use of alkylating agents
HK1088910A1 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
HUP0401756A3 (en) Substituted benzimidazole compounds and their use
IL164698A0 (en) Attenuation of metapneumovirus
AU2003279841A8 (en) Uses of human zven antagonists
PL373163A1 (en) Salt of (s)-pantoprazole and its hydrates
GB0207411D0 (en) Azole compounds and their therapeutic use
HK1087924A1 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
GB2387096B (en) Tomography of curved surfaces
IL162645A0 (en) solid salts benzazepine compounds and their use inthe preparation of pharmaceuticals compounds
IL163605A0 (en) Use of an inhibitor or antagonist against tissue factor
HUP0203929D0 (en) New use of substituted alkyl-piridazinone derivatives
SG127755A1 (en) Imidazoline compounds
GB0220215D0 (en) Compounds and their use
ZA200406552B (en) Use of an inhibitor or antagonist against tissue factor
PL363949A1 (en) Substituted benzoylcyclohexenones and their use as herbicidal agents
GB0207286D0 (en) Salt